Bank Hapoalim BM Reduces Position in Pfizer Inc. $PFE

Bank Hapoalim BM cut its stake in shares of Pfizer Inc. (NYSE:PFE) by 4.6% during the second quarter, Holdings Channel.com reports. The institutional investor owned 111,255 shares of the biopharmaceutical company’s stock after selling 5,363 shares during the quarter. Bank Hapoalim BM’s holdings in Pfizer were worth $2,697,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently added to or reduced their stakes in the company. GKV Capital Management Co. Inc. purchased a new stake in Pfizer in the first quarter valued at $27,000. North Capital Inc. purchased a new stake in Pfizer in the first quarter valued at $28,000. Bayforest Capital Ltd purchased a new stake in Pfizer in the first quarter valued at $28,000. Horizon Financial Services LLC purchased a new stake in Pfizer in the first quarter valued at $35,000. Finally, WPG Advisers LLC purchased a new stake in Pfizer in the first quarter valued at $35,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Trading Up 1.1%

PFE stock opened at $27.37 on Friday. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The company’s 50-day simple moving average is $24.67 and its 200-day simple moving average is $24.15. The firm has a market cap of $155.59 billion, a P/E ratio of 14.56, a PEG ratio of 0.88 and a beta of 0.55.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter in the prior year, the firm earned $0.60 EPS. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have commented on PFE. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Bank of America upped their price target on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research note on Saturday, September 27th. Morgan Stanley increased their target price on shares of Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 6th. Finally, Citigroup increased their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $28.41.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.